Table 3.
Change in Beck Depression Inventory-II (Δ BDI-II) scores (score at the end of the study minus score at baseline) in relation to baseline and final serum 25-hydroxyvitamin D (25(OH)D) levels and baseline BDI-II scores*
(Mean values and standard deviations)
| Vitamin D group | Placebo group | |||||
|---|---|---|---|---|---|---|
| Δ BDI-II score | Δ BDI-II score | |||||
| n | Mean | sd | n | Mean | sd | |
| All subjects regardless of baseline and final 25(OH)D levels | ||||||
| Regardless of baseline BDI-II score | 208 | −1·5 | 4·3 | 202 | −1·9 | 4·1 |
| Baseline BDI-II score >4 | 100 | −3·2 | 5·2 | 93 | −3·8 | 5·0 |
| Baseline BDI-II score >10 | 18 | −7·1 | 5·5 | 27 | −4·9 | 7·4 |
| Subjects with baseline 25(OH)D < 50 nmol/l, and final 25(OH)D >70 nmol/l in the vitamin D group and final 25(OH)D <50 nmol/l in the placebo group | ||||||
| Regardless of baseline BDI-II score | 163 | −1·4 | 4·4 | 165 | −2·0 | 4·3 |
| Baseline BDI-II score >4 | 76 | −3·1 | 5·5 | 76 | −4·0 | 5·2 |
| Baseline BDI-II score >10 | 15 | −6·6 | 5·5 | 24 | −5·1 | 7·4 |
| Subjects with baseline 25(OH)D < 40 nmol/l, and final 25(OH)D > 70 nmol/l in the vitamin D group and final 25(OH)D < 40 nmol/l in the placebo group | ||||||
| Regardless of baseline BDI-II score | 136 | −1·9 | 4·2 | 126 | −2·4 | 4·2 |
| Baseline BDI-II score > 4 | 66 | −3·8 | 5·0 | 57 | −4·7 | 4·9 |
| Baseline BDI-II score > 10 | 14 | −7·1 | 5·4 | 17 | −6·4 | 6·4 |
| Subjects with baseline 25(OH)D < 30 nmol/l, and final 25(OH)D > 70 nmol/l in the vitamin D group and final 25(OH)D < 30 nmol/l in the placebo group | ||||||
| Regardless of baseline BDI-II score | 74 | −1·3 | 3·6 | 52 | −2·0 | 4·5 |
| Baseline BDI-II score >4 | 36 | −2·6 | 4·6 | 23 | −4·4 | 5·1 |
| Baseline BDI-II score >10 | 7 | −5·4 | 2·5 | 7 | −6·7 | 5·4 |
*
Vitamin D analysed v. corresponding placebo group with linear regression with baseline value, age and sex as covariates. P > 0·05 for all comparisons.